Tianjin Chase Sun PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Tianjin Chase Sun PharmaceuticalLtd's earnings have been declining at an average annual rate of -0.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.1% per year. Tianjin Chase Sun PharmaceuticalLtd's return on equity is 2%, and it has net margins of 2.9%.
Key information
-0.1%
Earnings growth rate
-0.3%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 2.1% |
Return on equity | 2.0% |
Net Margin | 2.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tianjin Chase Sun PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 5,627 | 166 | 2,436 | 210 |
30 Jun 24 | 5,682 | 309 | 2,390 | 203 |
31 Mar 24 | 5,913 | 389 | 2,450 | 204 |
31 Dec 23 | 6,109 | 507 | 2,515 | 210 |
30 Sep 23 | 6,672 | 663 | 2,826 | 209 |
30 Jun 23 | 6,762 | 617 | 2,971 | 220 |
31 Mar 23 | 6,577 | 561 | 2,859 | 229 |
01 Jan 23 | 6,650 | 624 | 2,807 | 231 |
30 Sep 22 | 7,084 | 521 | 3,026 | 257 |
30 Jun 22 | 7,496 | 602 | 3,099 | 231 |
31 Mar 22 | 7,764 | 732 | 3,133 | 207 |
31 Dec 21 | 7,671 | 687 | 3,128 | 197 |
30 Sep 21 | 7,266 | 611 | 2,837 | 197 |
30 Jun 21 | 7,192 | 667 | 2,846 | 198 |
31 Mar 21 | 7,001 | 657 | 2,811 | 195 |
31 Dec 20 | 6,488 | 573 | 2,717 | 177 |
30 Sep 20 | 6,109 | 485 | 2,708 | 161 |
30 Jun 20 | 5,497 | 396 | 2,565 | 161 |
31 Mar 20 | 5,085 | 337 | 2,553 | 174 |
31 Dec 19 | 5,003 | 403 | 2,534 | 179 |
30 Sep 19 | 4,796 | 264 | 2,513 | 166 |
30 Jun 19 | 4,548 | 216 | 2,412 | 161 |
31 Mar 19 | 4,303 | 219 | 2,267 | 143 |
31 Dec 18 | 4,224 | 211 | 2,210 | 141 |
30 Sep 18 | 4,015 | 463 | 2,016 | 126 |
30 Jun 18 | 3,894 | 514 | 1,876 | 161 |
31 Mar 18 | 3,605 | 485 | 1,713 | 134 |
31 Dec 17 | 3,374 | 451 | 1,618 | 109 |
30 Sep 17 | 3,543 | 633 | 1,694 | 70 |
30 Jun 17 | 3,564 | 630 | 1,818 | 0 |
31 Mar 17 | 3,743 | 666 | 1,982 | 0 |
31 Dec 16 | 3,867 | 659 | 2,100 | 0 |
30 Sep 16 | 3,722 | 582 | 2,211 | 0 |
30 Jun 16 | 3,635 | 599 | 2,195 | 0 |
31 Mar 16 | 3,596 | 572 | 2,237 | 0 |
31 Dec 15 | 3,348 | 535 | 2,153 | 0 |
30 Sep 15 | 3,187 | 541 | 1,988 | 0 |
30 Jun 15 | 3,076 | 474 | 1,961 | 0 |
31 Mar 15 | 2,969 | 452 | 1,922 | 0 |
31 Dec 14 | 2,864 | 447 | 1,860 | 0 |
30 Sep 14 | 2,681 | 421 | 1,756 | 0 |
30 Jun 14 | 2,405 | 395 | 1,562 | 0 |
31 Mar 14 | 2,201 | 362 | 1,418 | 0 |
31 Dec 13 | 2,097 | 340 | 1,349 | 0 |
Quality Earnings: 300026 has a large one-off gain of CN¥143.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 300026's current net profit margins (2.9%) are lower than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300026's earnings have declined by 0.1% per year over the past 5 years.
Accelerating Growth: 300026's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300026 had negative earnings growth (-75%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 300026's Return on Equity (2%) is considered low.